Nurix Therapeutics, Inc.
NRIX
Jodie situation report
Nurix Therapeutics, Inc.'s move is being confirmed by its market group.
No new filing conclusion is available. 14 of 18 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 5 directly disclosed connections are confirming.
- At least 12 of 18 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as ROIV begins moving with the group.
Invalidation: The live read weakens if participation falls to 6 of 18 members or fewer.
Who this business touches
The relationships behind NRIX
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
PFEPfizer, Inc.partnerApr 8, 2026 ▾
“Pfizer In September 2023, we entered into a strategic collaboration with Seagen Inc.”
SNYSanofipartnerApr 8, 2026 ▾
“Sanofi In December 2019, we entered into a strategic collaboration with Genzyme Corporation, a subsidiary of Sanofi, which became effective in January 2020 (as subsequently expanded and amended, the Sanofi Agreement), to discover, develop and commercialize a…”
GILDGilead Sciences, Inc.partnerApr 8, 2026 ▾
“In August 2019 and September 2022, we entered into the First Amendment and the Second Amendment, respectively, to the Gilead Agreement to clarify certain language of the Gilead Agreement.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 5 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
NRIX is currently a Participant in the organic co-movement group Biotech Rare Diseases. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.